Groups
Company Size (Fulltime employees)
Looking for
Functionality
Headquartner in China
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Medtech Category
Medtech Development Stage
Index
Countries
Reset

Dan Ring United States

We are a late-stage biopharmaceutical company committed to developing and commercializing products to treat rare diseases where there is an unmet medical need.
Website:
https://www.soligenix.com/
Stock Market and Ticker/Symbol/Number
SNGX
Looking for
Please specify your partnering goal
Out licensing CTCL program
Headquartner in China
No
Biotech/Pharma Category
Assets Information 1: Name|Description|Indications|Stage|IP countries
Hypericin||CTCL|Ph 3 completed|
Biotech/Pharma Asset Stage
Soligenix, Inc.
Vice President, Business Development & Strategic Planning 
Functionality
Business Development

Christer Rosen United States

JOT is a virtual company with its base operation in Jupiter, FL. JOT is in position to quickly come to market with a platform product effective to treat 12 or more indications including Alzheimer’s Disease. The proprietary patented product, JOTROL, is very safe, oral, naturally based and multi-functional. JOTROL will be very effective with high social and economic impact within a reasonable timeframe. Relationships have been developed with scientists at various institutions, such as University of Miami (“UM”), MIT, Harvard, Georgetown University and Murdoch Childrens Research Institute, AU. This setup has made it possible to gain access to laboratory work, scientific information, pre-clinical development and scientific expertise in an extremely cost effective and efficient way. JOT will conclude clinical trials by utilizing a contract manufacturer and Clinical Research Organizations, involvement by its scientific advisors as well as support from patient organizations thereby keeping its fixed overhead extremely low for a Biotech company. A Phase I trial is presently ongoing with results expected in Q1,2021. Two Phase II rare disease trials, are expected to be started in H2 of 2021 with possible accelerated approvals from FDA. Partial financing for those are expected to be received from NIH. A Phase II trial in Alzheimer’s is also planned to be executed in parallel. Financing for the Phase I study has been granted by NIA (National Institute of Aging). Financing for a larger Phase II study is also expected to be financed by a NIA consortium (up to $75 million). JOT is prepared to add a commercial organization to market its product in North America while out-licensing marketing and sales operations for the rest of the world.
Website:
www.jupiterorphan.com
Company Size (Fulltime employees)
1-10
Year of foundation
2016
Looking for
Please specify your partnering goal
Out-license our platform product to a reputable Chinese partner.
Funding Status
Series A
Now raising (In USD)
$15 Million
Headquartner in China
No
Plan in China
Out-license our JOTROL platform product applicable to 12 or more indications.
Biotech/Pharma Category
Assets Information 1: Name|Description|Indications|Stage|IP countries
JOTROL|Patented First and Only resveratrol product that can be disease modifying without side effects.|MPS-1, MELAS, Friedreich's ataxia and other ataxias, Mild Cognitive Impairment, Alzheimer's Disease|Phase I completed mid-March|N/A
Biotech/Pharma Asset Stage
Jupiter Orphan Therapeutics Inc. (JOT)
Chairman & CEO 
Functionality
Management

Heather Schwoebel United States

Alloy is making a humanized transgenic antibody discovery platform, developed within a large pharmaceutical company, broadly available. Our business model includes unlimited access under royalty free terms. Alloy’s strategic plan is to include additional platforms in the protein engineering space that can be synergistically incorporated into our platform, thereby increasing the value offered to licensees.
Website:
www.alloytx.com
Looking for
Headquartner in China
No
Plan in China
partnering and out-licensing
Alloy Therapeutics
Senior Director of BD 
Functionality
Business Development

h michael shepard United States

Enosi's lead programs involve novel inhibitors of TNF (tumor necrosis factor), which include severe inflammation associated with viral infections, autoimmune disease, fibrotic diseases, Alzheimer’s, cancer and other diseases. The current TNF inhibitors have important “Black Box” warnings for opportunistic infections, cancer, and cardiovascular events, like stroke. Enosi believes our compounds in development will avoid these limitations of current drugs, be more effective, and will allow expansion into many indications/markets that cannot be approached at the present time by current TNF inhibitors because of their side-effects.
Website:
enosi-life.com
Company Size (Fulltime employees)
1-10
Year of foundation
2020
Looking for
Please specify your partnering goal
Collaboration to discover and develop molecules for autoimmune disease and cancer
Headquartner in China
No
Plan in China
Seek collaborations to jointly develop products in cancer and autoimmune disease.
Biotech/Pharma Asset Stage
Medtech Development Stage
Enosi Life Sciences
CSO and CEO 
Functionality
Management

Dave Sheppard United States

MedWorld Advisors is an international M&A Services Firm. We represent medical technology companies from the US, EU and Israel that want to enter the China market. We facilitate licensing, commercialization and acquisition deals between our clients and larger companies / investors in China. We are based in Boston in the U.S. We also have an operation in Hong Kong to help facilitate deals, as helpful.
Website:
www.medworldadvisors.com
Company Size (Fulltime employees)
1-10
Year of foundation
2015
Looking for
Please specify your partnering goal
We currently have 10 Medical Technology projects that may be interesting for the China market. We seek to meet appropriate China partners for these projects.
Headquartner in China
No
Plan in China
We have projects in medical imaging, image processing, endoscopy, endo-vascular, hemodynamics, oximetry, digital health, wearables, and wound care that may be interesting for the China market.
Medtech Category
Medtech Information 1, Device Name|Description|Development Stage|Licensed Countries
Multiple Projects|Open for Licensing / Acquisition|FDA Cleared|US, EU and Israel
Medtech Development Stage
MedWorld Advisors
Managing Director 
Functionality
Business Development

George Simeon United States

Curevo is a clinical stage company dedicated to bringing next generation vaccines that offer effectiveness, safety, tolerability, and production advantages to the market, quickly and efficiently.
Curevo will combine excellence in protein science and adjuvant technology to speed safe and highly effective vaccines from the bench through clinical development.
Curevo will focus on vaccine-preventable illnesses that are common in both the Asian and US markets and for which current vaccine products are not available.
Curevo’s goal is to rapidly advance innovative new vaccine candidates from research laboratory to clinic by joining forces with South Korean Mogam Institute for Biomedical Research and GC Pharma.
Curevo's lead product, a Zoster (Shingles) Vaccine, has completed Phase I and shown promising results. We are targeting a unique position in the $20B (by 2030) Varicella Zoster Virus vaccine market.
Website:
www.curevovaccine.com
Company Size (Fulltime employees)
1-10
Year of foundation
2018
Looking for
Funding Status
Raising Series-A
Headquartner in China
No
Plan in China
As a premium and high margin segment, the shingles vaccine market represents a significant opportunity for local, regional, or global players.
Curevo Vaccine
CEO 
Functionality
Management

Syliva Siu United States

As China Focus conference organizer, MyBioGate is a premier cross-border healthcare consulting firm serving Biotech and Medtech clients, and the Chinese Pharma companies and investors. We offer marketing, strategy and execution support to help healthcare innovation to grow by taking advantage of China’s huge market potential. We help innovative companies with China-Landing services, and help them find reliable Chinese investors and partners. MyBioGate is committed to linking healthcare innovations in China and overseas. We share global healthcare innovation, entrepreneurship, investment trends, KOL opinions, important events and conferences, in-depth research and analysis, allowing Chinese medical and health companies and investors to gain insight into trends and seize investment opportunities. Our China Focus forums, Global Healthcare Innovation Competitions, and road shows to China provide innovative companies who intend to enter China market with platforms for exposure to potential investors and partners.

Website:
https://en.mybiogate.com/
Mybiogate Inc.

Aleksandr Stiblo United States

Global Clinical Trials (GCT) is a premium contract-research organization (CRO) that offers support for the clinical Phase I-IV studies as well as post-marketing activities to Big Pharma, small and medium-sized biotech enterprises, groups and funds, as well as large universities and institutions. Headquartered in Princeton, USA, GCT offers both local and global support through 10 own operational offices in Bulgaria, Czech Republic, Georgia, Hungary, India, Kazakhstan, Latvia, Lithuania, Estonia, Moldova, Poland, Romania, Russia, Slovakia, Ukraine.
GCT team, that now consists of over 100 full-time clinical research professionals, gives individualized attention to each project and provides full range of services following the latest GCP, EMA and FDA guidelines at every stage of product development path. Our monitors and project managers are all certified clinicians experienced in GCP clinical research. Our experience, competent staff, close contact with the KOLs and the immense enrollment potential of the covered region ensure fast study start-up and compliance with the set timelines.
GCT owns 400 sq.m. (4300 ft2) Drug Storage and Distribution facility in St. Petersburg, Russia. It is fully equipped, disaster protected and has multiple modes of storage (ambient, climate controlled, refrigerated, frozen). High standards of work and client satisfaction are proved by the fact that more than 80% of the business come from repeat clients.
Since 2006 GCT is also an Exclusive Partner of “The White Nights” International ophthalmology congress in Russia.
Website:
https://gctrials.com/
Company Size (Fulltime employees)
51-200
Year of foundation
2001
Stock Market and Ticker/Symbol/Number
N/A
Looking for
Please specify your partnering goal
Networking, new business opportunities
Headquartner in China
No
Plan in China
GCT is looking for potential new business opportunities, offering full-service clinical trials support worldwide for Chinese pharma companies.
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Medtech Development Stage
Your Service Name
clinical trials, market authorization, registration, consulting
Service Description
logistics, regulatory services, project and site management, pharmacovigilance, medical monitoring, data management, biostatistics, medical writing, GDPR and DPO, EU Legal representation,
Target Client Type
Pharma, Biotech, Device companies
Global Clinical Trials (GCT)
LinkedIn logo Director, Business Development 
Functionality
Business Development

Peilun Sun United States

Located at the High-Tech center, Silicon Valley, ZJ Future was established in 2013 as a bridge between China and the US to offer accelerating services for domestic enterprises with global perspectives. ​



With the vision of accelerating enterprise development and growth, we leverage the complementary advantages of North America, Europe, South America, and the Asia-Pacific regions to connect high-quality projects with industry leaders, promote academic communications and interactions in high-tech fields, aggregate global entrepreneurial and innovative resources, build an effective and efficient global innovation ecosystem, and develop high-level and multi-field cooperation in the fields of economy, trade, investment, science, and technology.
Website:
https://www.zjfutureus.com/
Looking for
Headquartner in China
Yes
Biotech/Pharma Category
Service Description
项目投资
ZJ Future
Investment Associate 

Kun Tao United States

As China Focus conference organizer, MyBioGate is a premier cross-border healthcare consulting firm serving Biotech and Medtech clients, and the Chinese Pharma companies and investors. We offer marketing, strategy and execution support to help healthcare innovation to grow by taking advantage of China’s huge market potential. We help innovative companies with China-Landing services, and help them find reliable Chinese investors and partners. MyBioGate is committed to linking healthcare innovations in China and overseas. We share global healthcare innovation, entrepreneurship, investment trends, KOL opinions, important events and conferences, in-depth research and analysis, allowing Chinese medical and health companies and investors to gain insight into trends and seize investment opportunities. Our China Focus forums, Global Healthcare Innovation Competitions, and road shows to China provide innovative companies who intend to enter China market with platforms for exposure to potential investors and partners.

Website:
https://en.mybiogate.com/
Mybiogate Inc.
Functionality
Investment